Managing cognitive impairment in Parkinson’s disease: an update of the literature
Управление когнитивными нарушениями при болезни Паркинсона: обзор литературы
2025-01-07
SCID: 54.1/f22u469e
Discuss with AI
Parkinson's disease cognitive impairmentParkinson's disease dementiacognitive evaluations and criteriapathobiology of PD cognitive impairmentvalidated biomarkers for cognitive change
Figures from the paper
Abstract (AI)
While our understanding of cognitive dysfunction in PD has grown, effective and safe therapeutics are still needed to not only treat cognitive impairment and dementia symptomatically but also slow down or prevent cognitive decline. Further research is needed to elucidate the pathobiology of PD cognitive impairment, develop validated biomarkers reflecting cognitive change, and ultimately, integrate clinical and biological frameworks. Consensus regarding cognitive evaluations, definitions, and criteria of cognitive impairment, evaluating functional abilities in the context of cognitive impairment, and determining optimal outcome measures for clinical trials remain unmet needs.
Key Findings
1
Effective and safe therapeutics for treating or preventing cognitive impairment and dementia in Parkinson’s disease are still lacking.
2
Further research is required to elucidate the pathobiology of cognitive impairment in Parkinson’s disease.
3
Integration of clinical and biological frameworks for Parkinson’s disease cognitive impairment is a required future goal.
4
Optimal methods to evaluate functional abilities in the context of cognitive impairment and appropriate clinical trial outcome measures remain unmet needs.
5
There is no consensus on cognitive evaluations, definitions, and criteria for cognitive impairment in Parkinson’s disease.
6
Validated biomarkers that reflect cognitive change in Parkinson’s disease are not yet established and need development.
Research Object
Cognitive impairment in Parkinson’s disease patients
Research Subject
Management strategies, therapeutic development, biomarker validation, clinical/biological frameworks, and outcome assessment for treating, slowing, or preventing cognitive decline and dementia in Parkinson’s disease
Publication Details
Publication Date
2025-01-07
Journal
Publisher
ISSN
Cited by
7
Access Type
Author Information
Download PDF
Subscribe to digest